Eagle Pharmaceuticals is a specialty pharmaceutical company, focusing on developing and commercializing injectable products primarily in the critical care and oncology areas. The Company offers argatroban for heparin-induced thrombocytopenia, Ryanodex for malignant hyperthermia, non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head and neck cancers/gastric adenocarcinoma, as well as Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.
Revenue (Q1, 2018)
Gross profit (Q1, 2018)
Gross profit margin (Q1, 2018), %
Net income (Q1, 2018)
EBIT (Q1, 2018)
Market capitalization (15-May-2018)
Closing share price (15-May-2018)